RHOEN-KLINIKUM AG (RHK.DE) Fundamental Analysis & Valuation

FRA:RHKDE0007042301

Current stock price

12.3 EUR
0 (0%)
Last:

This RHK.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. RHK.DE Profitability Analysis

1.1 Basic Checks

  • RHK had positive earnings in the past year.
  • In the past year RHK had a positive cash flow from operations.
  • RHK had positive earnings in each of the past 5 years.
  • In the past 5 years RHK always reported a positive cash flow from operatings.
RHK.DE Yearly Net Income VS EBIT VS OCF VS FCFRHK.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M -100M

1.2 Ratios

  • With a Return On Assets value of 1.89%, RHK is not doing good in the industry: 64.29% of the companies in the same industry are doing better.
  • The Return On Equity of RHK (2.61%) is worse than 71.43% of its industry peers.
  • RHK has a Return On Invested Capital of 2.24%. This is in the lower half of the industry: RHK underperforms 75.00% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for RHK is below the industry average of 6.23%.
Industry RankSector Rank
ROA 1.89%
ROE 2.61%
ROIC 2.24%
ROA(3y)2.14%
ROA(5y)1.92%
ROE(3y)3.02%
ROE(5y)2.69%
ROIC(3y)2.41%
ROIC(5y)2.18%
RHK.DE Yearly ROA, ROE, ROICRHK.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2 4 6

1.3 Margins

  • RHK's Profit Margin of 2.02% is on the low side compared to the rest of the industry. RHK is outperformed by 60.71% of its industry peers.
  • RHK's Profit Margin has improved in the last couple of years.
  • The Operating Margin of RHK (2.40%) is worse than 78.57% of its industry peers.
  • RHK's Operating Margin has improved in the last couple of years.
  • RHK has a better Gross Margin (66.87%) than 71.43% of its industry peers.
  • RHK's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 2.4%
PM (TTM) 2.02%
GM 66.87%
OM growth 3Y1.67%
OM growth 5Y10.96%
PM growth 3Y5.16%
PM growth 5Y80.11%
GM growth 3Y-1.1%
GM growth 5Y-0.61%
RHK.DE Yearly Profit, Operating, Gross MarginsRHK.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

7

2. RHK.DE Health Analysis

2.1 Basic Checks

  • RHK has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • Compared to 1 year ago, RHK has about the same amount of shares outstanding.
  • RHK has about the same amout of shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, RHK has an improved debt to assets ratio.
RHK.DE Yearly Shares OutstandingRHK.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
RHK.DE Yearly Total Debt VS Total AssetsRHK.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

2.2 Solvency

  • An Altman-Z score of 3.25 indicates that RHK is not in any danger for bankruptcy at the moment.
  • With an excellent Altman-Z score value of 3.25, RHK belongs to the best of the industry, outperforming 85.71% of the companies in the same industry.
  • A Debt/Equity ratio of 0.09 indicates that RHK is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.09, RHK belongs to the top of the industry, outperforming 92.86% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z 3.25
ROIC/WACC0.33
WACC6.74%
RHK.DE Yearly LT Debt VS Equity VS FCFRHK.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B

2.3 Liquidity

  • A Current Ratio of 2.60 indicates that RHK has no problem at all paying its short term obligations.
  • RHK has a better Current ratio (2.60) than 96.43% of its industry peers.
  • A Quick Ratio of 2.49 indicates that RHK has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 2.49, RHK belongs to the best of the industry, outperforming 96.43% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.6
Quick Ratio 2.49
RHK.DE Yearly Current Assets VS Current LiabilitesRHK.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

5

3. RHK.DE Growth Analysis

3.1 Past

  • The earnings per share for RHK have decreased strongly by -21.07% in the last year.
  • Measured over the past years, RHK shows a very strong growth in Earnings Per Share. The EPS has been growing by 88.40% on average per year.
  • RHK shows a small growth in Revenue. In the last year, the Revenue has grown by 6.84%.
  • Measured over the past years, RHK shows a small growth in Revenue. The Revenue has been growing by 4.62% on average per year.
EPS 1Y (TTM)-21.07%
EPS 3Y11.09%
EPS 5Y88.4%
EPS Q2Q%-25.1%
Revenue 1Y (TTM)6.84%
Revenue growth 3Y5.64%
Revenue growth 5Y4.62%
Sales Q2Q%4.24%

3.2 Future

  • The Earnings Per Share is expected to grow by 13.44% on average over the next years. This is quite good.
  • RHK is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.72% yearly.
EPS Next Y17.01%
EPS Next 2Y14.65%
EPS Next 3Y13.68%
EPS Next 5Y13.44%
Revenue Next Year3.87%
Revenue Next 2Y6.19%
Revenue Next 3Y5.92%
Revenue Next 5Y5.72%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
RHK.DE Yearly Revenue VS EstimatesRHK.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 500M 1B 1.5B 2B
RHK.DE Yearly EPS VS EstimatesRHK.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0.2 0.4 0.6 0.8 1

3

4. RHK.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 24.12 indicates a rather expensive valuation of RHK.
  • Compared to the rest of the industry, the Price/Earnings ratio of RHK indicates a slightly more expensive valuation: RHK is more expensive than 64.29% of the companies listed in the same industry.
  • RHK is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.66, which is the current average of the S&P500 Index.
  • Based on the Price/Forward Earnings ratio of 16.09, the valuation of RHK can be described as correct.
  • RHK's Price/Forward Earnings ratio is in line with the industry average.
  • When comparing the Price/Forward Earnings ratio of RHK to the average of the S&P500 Index (38.00), we can say RHK is valued rather cheaply.
Industry RankSector Rank
PE 24.12
Fwd PE 16.09
RHK.DE Price Earnings VS Forward Price EarningsRHK.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, RHK is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.3
RHK.DE Per share dataRHK.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20 25

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • RHK's earnings are expected to grow with 13.68% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.42
PEG (5Y)0.27
EPS Next 2Y14.65%
EPS Next 3Y13.68%

3

5. RHK.DE Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 1.63%, RHK has a reasonable but not impressive dividend return.
  • Compared to an average industry Dividend Yield of 1.84, RHK has a dividend in line with its industry peers.
  • Compared to an average S&P500 Dividend Yield of 1.81, RHK has a dividend comparable with the average S&P500 company.
Industry RankSector Rank
Dividend Yield 1.63%

5.2 History

  • The dividend of RHK decreases each year by -19.15%.
Dividend Growth(5Y)-19.15%
Div Incr Years1
Div Non Decr Years1
RHK.DE Yearly Dividends per shareRHK.DE Yearly Dividends per shareYearly Dividends per share 2019 2023 2025 2026 0.05 0.1 0.15 0.2 0.25

5.3 Sustainability

  • 19.44% of the earnings are spent on dividend by RHK. This is a low number and sustainable payout ratio.
DP19.44%
EPS Next 2Y14.65%
EPS Next 3Y13.68%
RHK.DE Yearly Income VS Free CF VS DividendRHK.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M -100M
RHK.DE Dividend Payout.RHK.DE Dividend Payout, showing the Payout Ratio.RHK.DE Dividend Payout.PayoutRetained Earnings

RHK.DE Fundamentals: All Metrics, Ratios and Statistics

RHOEN-KLINIKUM AG

FRA:RHK (4/21/2026, 7:00:00 PM)

12.3

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)03-26
Earnings (Next)05-07
Inst Owners0.53%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap823.61M
Revenue(TTM)1.70B
Net Income(TTM)34.47M
Analysts74.29
Price Target14.45 (17.48%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.63%
Yearly Dividend0.1
Dividend Growth(5Y)-19.15%
DP19.44%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.11%
Revenue NY rev (3m)-0.11%
Valuation
Industry RankSector Rank
PE 24.12
Fwd PE 16.09
P/S 0.48
P/FCF N/A
P/OCF 14.4
P/B 0.62
P/tB 0.71
EV/EBITDA 0.3
EPS(TTM)0.51
EY4.15%
EPS(NY)0.76
Fwd EY6.21%
FCF(TTM)-0.63
FCFYN/A
OCF(TTM)0.85
OCFY6.95%
SpS25.46
BVpS19.72
TBVpS17.21
PEG (NY)1.42
PEG (5Y)0.27
Graham Number15.0438 (22.31%)
Profitability
Industry RankSector Rank
ROA 1.89%
ROE 2.61%
ROCE 2.77%
ROIC 2.24%
ROICexc 3.53%
ROICexgc 4.31%
OM 2.4%
PM (TTM) 2.02%
GM 66.87%
FCFM N/A
ROA(3y)2.14%
ROA(5y)1.92%
ROE(3y)3.02%
ROE(5y)2.69%
ROIC(3y)2.41%
ROIC(5y)2.18%
ROICexc(3y)3.18%
ROICexc(5y)2.84%
ROICexgc(3y)3.77%
ROICexgc(5y)3.38%
ROCE(3y)2.99%
ROCE(5y)2.71%
ROICexgc growth 3Y5.1%
ROICexgc growth 5Y14.06%
ROICexc growth 3Y5.79%
ROICexc growth 5Y14.64%
OM growth 3Y1.67%
OM growth 5Y10.96%
PM growth 3Y5.16%
PM growth 5Y80.11%
GM growth 3Y-1.1%
GM growth 5Y-0.61%
F-Score6
Asset Turnover0.94
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA 1.12
Cap/Depr 152.7%
Cap/Sales 5.81%
Interest Coverage 13.22
Cash Conversion 54.02%
Profit Quality N/A
Current Ratio 2.6
Quick Ratio 2.49
Altman-Z 3.25
F-Score6
WACC6.74%
ROIC/WACC0.33
Cap/Depr(3y)120.3%
Cap/Depr(5y)111.07%
Cap/Sales(3y)4.84%
Cap/Sales(5y)4.82%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-21.07%
EPS 3Y11.09%
EPS 5Y88.4%
EPS Q2Q%-25.1%
EPS Next Y17.01%
EPS Next 2Y14.65%
EPS Next 3Y13.68%
EPS Next 5Y13.44%
Revenue 1Y (TTM)6.84%
Revenue growth 3Y5.64%
Revenue growth 5Y4.62%
Sales Q2Q%4.24%
Revenue Next Year3.87%
Revenue Next 2Y6.19%
Revenue Next 3Y5.92%
Revenue Next 5Y5.72%
EBIT growth 1Y-15.46%
EBIT growth 3Y7.4%
EBIT growth 5Y16.08%
EBIT Next Year147.39%
EBIT Next 3Y44.65%
EBIT Next 5Y34.3%
FCF growth 1Y-173.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-55.17%
OCF growth 3Y-1.74%
OCF growth 5Y-12.78%

RHOEN-KLINIKUM AG / RHK.DE Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for RHOEN-KLINIKUM AG?

ChartMill assigns a fundamental rating of 5 / 10 to RHK.DE.


What is the valuation status of RHOEN-KLINIKUM AG (RHK.DE) stock?

ChartMill assigns a valuation rating of 3 / 10 to RHOEN-KLINIKUM AG (RHK.DE). This can be considered as Overvalued.


How profitable is RHOEN-KLINIKUM AG (RHK.DE) stock?

RHOEN-KLINIKUM AG (RHK.DE) has a profitability rating of 4 / 10.


How financially healthy is RHOEN-KLINIKUM AG?

The financial health rating of RHOEN-KLINIKUM AG (RHK.DE) is 7 / 10.


What is the earnings growth outlook for RHOEN-KLINIKUM AG?

The Earnings per Share (EPS) of RHOEN-KLINIKUM AG (RHK.DE) is expected to grow by 17.01% in the next year.